Self‐Propelled Ultrasmall AuNPs‐Tannic Acid Hybrid Nanozyme with ROS‐Scavenging and Anti‐Inflammatory Activity for Drug‐Induced Liver Injury Alleviation
Small · 2023
DOI: 10.1002/smll.202206408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Chunyu Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, P. R. China. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Metal Nanoparticles. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Venture and Innovation Support Program for Chongqing Overseas Returnees, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
Developing nanomedicines with superior reactive oxygen species (ROS) scavenging capability has emerged as a promising strategy in treating ROS‐related diseases, for example, drug‐induced liver injury. However, designing nanoscavengers with the self‐propelling ability to scavenge ROS actively remains challenging. Here, a self‐propelled silica‐supported ultrasmall gold nanoparticles‐tannic acid hybrid nanozyme (SAuPTB) is designed that can effectively alleviate acetaminophen (APAP)‐induced liver injury by scavenging excessive ROS and regulating inflammation. SAuPTB exhibits multienzyme activity and displays significantly enhanced diffusion under hydrogen peroxide (H 2 O 2 ). This in vitro research shows that SAuPTB can effectively eliminate ROS, increasing the viability of H 2 O 2 ‐stimulated cells and reducing the cytotoxicity of APAP/H 2 O 2 ‐treated AML12 cells. The in vivo studies show that SAuPTB can accumulate at inflammatory sites in mouse liver, resulting in the decrease of alanine aminotransferase, aspartate aminotransferase, and ROS, reduction in pro‐inflammatory cytokines and chemokines, hence reduced hepatocyte necrosis, liver injury, and mortality. Furthermore, SAuPTB activates the nuclear erythroid 2‐related factor 2 pathway to upregulate antioxidative genes and reduce oxidative stress. Finally, the liver shows decreased high mobility group box 1 and F4/80 + macrophages, suggesting an anti‐inflammatory response. This work provides a novel design strategy of nanozymes for ROS‐related disease treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, P. R. China.
ORCID-Profile: Chunyu Zhou
Förderung
- National Natural Science Foundation of China
- Venture and Innovation Support Program for Chongqing Overseas Returnees
- Natural Science Foundation of Chongqing
Zitieren
APA
Zhou, C., Zhang, L., Xu, Z., Sun, T., Gong, M., Liu, Y., & Zhang, D. (2023). Self‐Propelled Ultrasmall AuNPs‐Tannic Acid Hybrid Nanozyme with ROS‐Scavenging and Anti‐Inflammatory Activity for Drug‐Induced Liver Injury Alleviation. Small. https://doi.org/10.1002/smll.202206408
Vancouver
Zhou C, Zhang L, Xu Z, Sun T, Gong M, Liu Y, et al. Self‐Propelled Ultrasmall AuNPs‐Tannic Acid Hybrid Nanozyme with ROS‐Scavenging and Anti‐Inflammatory Activity for Drug‐Induced Liver Injury Alleviation. Small. 2023. doi:10.1002/smll.202206408
BibTeX
@article{Zhou2023,
author = {Zhou, Chunyu and Zhang, Liang and Xu, Zhongsheng and Sun, Tao and Gong, Mingfu and Liu, Yun and Zhang, Dong},
title = {Self‐Propelled Ultrasmall AuNPs‐Tannic Acid Hybrid Nanozyme with ROS‐Scavenging and Anti‐Inflammatory Activity for Drug‐Induced Liver Injury Alleviation},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202206408}
}
EUVIMED